Salflumix Easyhaler – Medicinal Product Register of Latvia

Salmeteroli xinafoas, Fluticasoni propionas

Search by the name of the active substance

Medicinal product name	Salflumix Easyhaler 50 microgram/250 microgram/dose inhalation powder
Pharmaceutical form	Inhalation powder
Strength	50 µg/250 µg/dose
Information from the MAH on shortages	Not notified
Legal status	Rx Prescription (Pr.)
Package leaflet	12-04-2018
Summary of product characteristics	25-04-2019
ATC code	R03AK06 – Drugs for obstructive airway diseases

Important notice

Additional information regarding the use for persons aged 75+

If used as "DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES"
Substance	Class	Comment
Salmeteroli xinafoas	A	Suitable for older adults. Potentiates sympathomimetic effects. May cause hypokalaemia.
Fluticasoni propionas	A	Suitable for older adults. Consider possible systemic adverse effects with high doses.

Medicinal products (6)

Display only medicinal products with a declared price

Display only medicinal products available in wholesalers' stock

Availability of medicinal product	Wholesalers	Package size, content	Primary packaging	Product No.	Labelling
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N1: 1 × 60 (50 µg/250 µg/dose)	Inhaler	18-0072-01	Labelling text Sep 1, 2020
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N2: 2 × 60 (50 µg/250 µg/dose)	Inhaler	18-0072-02	Labelling text Sep 1, 2020
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N3: 3 × 60 (50 µg/250 µg/dose)	Inhaler	18-0072-03	Labelling text Sep 1, 2020
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N1: 1 × 60 (50 µg/250 µg/dose)	Inhaler and protective cover	18-0072-04	Labelling text Sep 1, 2020
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N2: 2 × 60 (50 µg/250 µg/dose)	Inhaler and protective cover	18-0072-05	Labelling text Sep 1, 2020
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N3: 3 × 60 (50 µg/250 µg/dose)	Inhaler and protective cover	18-0072-06	Labelling text Sep 1, 2020

Registration information

Marketing authorisation No.	18-0072
Date of authorisation	Apr 17, 2018
Marketing authorisation holder, country	Orion Corporation, Finland

Return to the results

Icon explanation

– Medicine is available
– Medicine is not available
– Distribution permitted for a limited time span
– Without a prescription
– Prescription medicine

– Medicine is listed on the Latvian National Health Service (NHS) list of state reimbursed medicines. (source of the information – the NHS)
– Reference medicine on the NHS List of state reimbursed medicines
– Lowest cost medicine within its therapeutic effectiveness class in cases where no reference medicine is available
- – Next lowest cost medicine after or (in ascending order)

Class A A (green): Suitable for the older persons. The medicinal substance can be used as in younger patients. Changes due to aging do not affect the dose or frequency of administration, and the adverse reaction profile is not different from that of younger patients.

Class B B (grey): There is little research evidence, practical experience or efficacy in older persons.

Class C C (yellow): Suitable for older persons, with specific cautions. The medicinal substance can be used by older persons, but the dose might either have to be reduced, or the frequency of administration decreased due to mild or moderate renal insufficiency or a significant risk of interactions or adverse reactions.

Class D D (red): Avoid use in older persons. Use is possible only in exceptional cases or on a one-off basis. Changes due to aging predispose older persons to adverse or dangerous reactions to the drug. The risk of adverse reactions typically exceeds the benefits.

Meds75+ data source is Finnish Medicines Agency Fimea (licensed under CC BY 4.0).
Data updated on Apr 30, 2024.